[go: up one dir, main page]

MX2017009849A - Composiciones de profármaco de monometilfumarato. - Google Patents

Composiciones de profármaco de monometilfumarato.

Info

Publication number
MX2017009849A
MX2017009849A MX2017009849A MX2017009849A MX2017009849A MX 2017009849 A MX2017009849 A MX 2017009849A MX 2017009849 A MX2017009849 A MX 2017009849A MX 2017009849 A MX2017009849 A MX 2017009849A MX 2017009849 A MX2017009849 A MX 2017009849A
Authority
MX
Mexico
Prior art keywords
compositions
propharmaco
monometilfumarate
formula
compounds
Prior art date
Application number
MX2017009849A
Other languages
English (en)
Other versions
MX382175B (es
Inventor
K Perkin Kristopher
Browning Ivan
S Manser David
Kirtikumar Shah Hardik
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54066160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017009849(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of MX2017009849A publication Critical patent/MX2017009849A/es
Publication of MX382175B publication Critical patent/MX382175B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente invención proporciona composiciones farmacéuticas que comprenden compuestos de Fórmula (I) y los métodos para el tratamiento de trastornos neurológicos, que comprenden administrar a un sujeto que lo necesite una composición farmacéutica que comprende un compuesto de Fórmula (I). Ver fórmula.
MX2017009849A 2015-02-08 2015-03-10 Composiciones de profármaco de monometilfumarato MX382175B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562113496P 2015-02-08 2015-02-08
PCT/IB2015/000731 WO2016124960A1 (en) 2015-02-08 2015-03-10 Monomethylfumarate prodrug compositions

Publications (2)

Publication Number Publication Date
MX2017009849A true MX2017009849A (es) 2017-12-11
MX382175B MX382175B (es) 2025-03-13

Family

ID=54066160

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009849A MX382175B (es) 2015-02-08 2015-03-10 Composiciones de profármaco de monometilfumarato

Country Status (25)

Country Link
US (4) US20160228376A1 (es)
EP (1) EP3253377B1 (es)
JP (3) JP2018503651A (es)
KR (1) KR102487136B1 (es)
CN (1) CN107205985A (es)
AU (3) AU2015381240A1 (es)
BR (1) BR112017016378A2 (es)
CA (1) CA2972179C (es)
CY (1) CY1124419T1 (es)
DK (1) DK3253377T3 (es)
EA (1) EA037666B1 (es)
ES (1) ES2879611T3 (es)
HR (1) HRP20211269T1 (es)
HU (1) HUE055210T2 (es)
IL (2) IL252962B (es)
LT (1) LT3253377T (es)
MX (1) MX382175B (es)
PL (1) PL3253377T3 (es)
PT (1) PT3253377T (es)
RS (1) RS62186B1 (es)
SG (3) SG11201705124QA (es)
SI (1) SI3253377T1 (es)
SM (1) SMT202100443T1 (es)
UA (1) UA121323C2 (es)
WO (1) WO2016124960A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102675526B1 (ko) 2019-01-30 2024-06-14 (주)애거슨바이오 모노메틸 푸마레이트 전구체 약물 화합물 및 이들의 약학적 조성물
WO2020198940A1 (zh) * 2019-03-29 2020-10-08 深圳仁泰医药科技有限公司 2-(2,5-二氧代吡咯烷-1基)乙基甲基富马酸酯的晶型a及其制备方法和应用
WO2020214693A1 (en) 2019-04-17 2020-10-22 Ixchel Pharma, Llc Prodrugs of monomethyl fumarate
MX2021012441A (es) * 2019-05-31 2022-10-07 Curacle Co Ltd Tableta enterica que contiene fumarato de dimetilo.
TW202116297A (zh) * 2019-07-03 2021-05-01 西班牙商布爾奴爾法碼有限公司 組合療法之方法、組成物與套組
EP4041218A4 (en) * 2019-09-16 2023-12-27 Glenmark Life Sciences Limited PROCESS FOR PREPARING DIROXIMEL FUMARATE
DE102020104243A1 (de) * 2020-02-18 2021-08-19 Research Center Pharmaceutical Engineering Gmbh Interferometrie mit niedriger Kohärenz an mit thermischen Herstellungsverfahren hergestellten Zusammensetzungen
US20240100088A1 (en) * 2021-01-31 2024-03-28 Alexion Pharmaceuticals, Inc. Novel formulation for treating copper metabolism-associated diseases or disorders
KR102566549B1 (ko) * 2021-06-08 2023-08-14 제이투에이치바이오텍 (주) 3성분 프로드럭, 이의 약학적 조성물 및 의약 용도
EP4355730A1 (en) * 2021-06-15 2024-04-24 Biogen MA Inc. Synthetic preparation for diroximel fumarate

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4482547A (en) * 1982-08-26 1984-11-13 Hoechst-Roussel Pharmaceuticals Inc. Substituted-1,3,4-benzotriazepines
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19814358C2 (de) 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
RU2290946C2 (ru) 2001-01-12 2007-01-10 Фумафарм Аг Амиды фумаровой кислоты
WO2004082684A1 (en) 2003-03-17 2004-09-30 Acorda Therapeutics Stable oral formulations of aminopyridines and uses thereof
DK1663197T3 (da) 2003-09-09 2008-01-07 Fumapharm Ag Anvendelse af fumarsyrederivater til behandling af hjerteinsuffiens og astma
DE10342423A1 (de) 2003-09-13 2005-04-14 Heidland, August, Prof. Dr.med. Dr.h.c. Verwendung von Fumarsäurederivaten zur Prophylaxe und zur Behandlung von Genomschäden
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
ES2582942T3 (es) * 2004-10-08 2016-09-16 Forward Pharma A/S Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
US8828429B2 (en) * 2005-03-03 2014-09-09 Takeda Pharmaceutical Company Limited Release-control composition
WO2007042034A1 (en) 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
JP5230610B2 (ja) 2006-05-05 2013-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 二価ｓｍａｃ模倣物およびその使用
CN104523673A (zh) 2009-04-29 2015-04-22 比奥根艾迪克Ma公司 神经变性和神经炎症的治疗
JP5733930B2 (ja) * 2009-09-09 2015-06-10 武田薬品工業株式会社 固形製剤
CN113244185A (zh) * 2012-02-07 2021-08-13 比奥根玛公司 含有富马酸二甲酯的药物组合物
WO2014031844A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
PT2970101T (pt) * 2013-03-14 2018-10-04 Alkermes Pharma Ireland Ltd Pró-fármacos de fumaratos e seu uso no tratamento de várias doenças
JP2016527276A (ja) 2013-08-01 2016-09-08 ゼノポート，インコーポレイティド 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法
CN104027311A (zh) * 2014-05-09 2014-09-10 万特制药(海南)有限公司 一种含有富马酸二甲酯的肠溶缓释微丸
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques

Also Published As

Publication number Publication date
AU2015381240A1 (en) 2017-07-06
AU2019200868A1 (en) 2019-02-28
SI3253377T1 (sl) 2021-08-31
JP7145918B2 (ja) 2022-10-03
HRP20211269T1 (hr) 2022-01-21
US20220257520A1 (en) 2022-08-18
ES2879611T3 (es) 2021-11-22
MX382175B (es) 2025-03-13
PL3253377T3 (pl) 2021-09-27
CA2972179A1 (en) 2016-08-11
US20190247315A1 (en) 2019-08-15
IL252962B (en) 2022-07-01
SG11201705124QA (en) 2017-07-28
BR112017016378A2 (pt) 2018-03-27
CA2972179C (en) 2021-10-26
US20250057770A1 (en) 2025-02-20
KR102487136B1 (ko) 2023-01-10
RS62186B1 (sr) 2021-08-31
AU2020205237B2 (en) 2022-04-14
KR20170115044A (ko) 2017-10-16
AU2020205237A1 (en) 2020-07-30
SMT202100443T1 (it) 2021-09-14
EA037666B1 (ru) 2021-04-28
DK3253377T3 (da) 2021-07-12
PT3253377T (pt) 2021-07-14
SG10201907289VA (en) 2019-09-27
JP2019031550A (ja) 2019-02-28
IL287830A (en) 2022-01-01
EP3253377B1 (en) 2021-05-12
CY1124419T1 (el) 2022-07-22
HUE055210T2 (hu) 2021-11-29
WO2016124960A1 (en) 2016-08-11
SG10201907291QA (en) 2019-09-27
LT3253377T (lt) 2021-08-25
US20160228376A1 (en) 2016-08-11
IL252962A0 (en) 2017-08-31
JP2018503651A (ja) 2018-02-08
JP2020203951A (ja) 2020-12-24
CN107205985A (zh) 2017-09-26
AU2019200868B2 (en) 2020-05-14
EP3253377A1 (en) 2017-12-13
UA121323C2 (uk) 2020-05-12
EA201791432A1 (ru) 2017-12-29

Similar Documents

Publication Publication Date Title
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
MX2018016273A (es) Compuestos heterociclicos como inmunomoduladores.
MX386826B (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
MX2018000916A (es) Derivados de benzodiazepina como inhibidores de rsv.
MX2018007774A (es) Compuestos heterociclicos como inmunomoduladores.
CU20170015A7 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
DOP2015000274A (es) Compuestos químicos
MX2019009695A (es) Inhibidores espirociclicos de catepsina c.
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
GT201400261A (es) Solicitud pct face nacional novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
GT201200004A (es) Imidazoles fusionados y composiciones que los contienen para el tratamiento de enfermedades parasitarias, como por ejemplo malaria
DOP2017000049A (es) Compuestos tricíclicos que contienen nitrógeno para el tratamiento de la infección por neisseria gonorrhoeae
ECSP14014778A (es) Composiciones derivadas de la quitosana
MX2016012041A (es) Formulaciones de aripiprazol que tienen mayores velocidades de inyeccion.